Preclinical and Clinical Testing Services for CPP

The contract seeks a subcontractor to conduct Good Laboratory Practice-compliant preclinical and clinical testing to evaluate the viability, hemostatic function, immunogenicity, and safety of a novel CPP product. The work includes both in vitro and in vivo studies with the potential to progress into Phase I/II clinical trials, ensuring the product meets regulatory standards for advancement. Testing must adhere to strict scientific and quality protocols to generate reliable data supporting further development and regulatory submissions. The opportunity is issued by the Army Medical Resources Acquisition Activity under the Department of Defense, with performance specifically required in Frederick, Maryland, at the indicated zip code. It is classified under NAICS code 541620, reflecting specialized scientific research and development services. The solicitation was posted on April 28, 2026, and responses are due by May 4, 2026, at 7:00 PM Eastern Time. This is a subcontract opportunity with no set-aside designation, and potential offerors must be prepared to deliver comprehensive, compliant testing services under tight timelines to support national medical research objectives.